Phase I trial of Wilms' tumor 1 (WT1) peptide vaccine with GM-CSF or CpG in patients with solid malignancy

Anticancer Research

Volumn 32, Issue 6, 2012, Pages 2263-2269

  Ohno, Satoshi ^a,b   Okuyama, Ryuji ^a   Aruga, Atsushi ^a   Sugiyama, Haruo ^c   Yamamoto, Masakazu ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b WASEDA UNIVERSITY   (Japan)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

Cancer vaccine; CpG oligodeoxynucleotides (CpG ODN); Granulocyte macrophage colony stimulating factor (GM CSF); Immunotherapy; Wilms' tumor 1 (WT1)

Indexed keywords

CANCER VACCINE; CPG OLIGODEOXYNUCLEOTIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA A ANTIGEN; MONTANIDE ISA 51; UNCLASSIFIED DRUG; WILMS TUMOR 1 PEPTIDE VACCINE; WT1 PROTEIN; DRUG DERIVATIVE; IMMUNOLOGICAL ADJUVANT; MANNITOL; OLEIC ACID; OLIGONUCLEOTIDE; SUBUNIT VACCINE;

ADJUVANT THERAPY; ADULT; ADVERSE OUTCOME; AGED; ARTICLE; BILE DUCT CANCER; CANCER IMMUNIZATION; CLINICAL ARTICLE; COLON CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPITHELIOID SARCOMA; ERYTHEMA; ESOPHAGUS CANCER; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMAN; INJECTION SITE REACTION; LUNG CANCER; MALE; MONOTHERAPY; OVARY CANCER; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECTUM CANCER; SOLID TUMOR; STOMACH CANCER; TREATMENT RESPONSE; TUMOR VOLUME; UTERINE CERVIX CANCER; CLINICAL TRIAL; CPG ISLAND; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; MIDDLE AGED; NEOPLASM;

ADJUVANTS, IMMUNOLOGIC; AGED; CANCER VACCINES; CPG ISLANDS; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MANNITOL; MIDDLE AGED; NEOPLASMS; OLEIC ACIDS; OLIGONUCLEOTIDES; VACCINES, SUBUNIT; WT1 PROTEINS;

EID: 84864571350     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Oka Y, Tsuboi A, Elisseeva OA, Udaka K and Sugiyama H: WT1 as a novel target antigen for cancer immunotherapy. Curr Cancer Drug Targets 2: 45-54, 2002.
2. Oka Y, Tsuboi A, Oji Y, Kawase I and Sugiyama H: WT1 peptide vaccine for the treatment of cancer. Curr Opin Immunol 20: 211-220, 2008.
3. Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo T, Nakajima H, Elisseeva OA, Oji Y, Kawakami M, Ikegame K, Hosen N, Yoshihara S, Wu F, Fujiki F, Murakami M, Masuda T, Nishida S, Shirakata T, Nakatsuka S, Sasaki A, Udaka K, Dohy H, Aozasa K, Noguchi S, Kawase I and Sugiyama H: Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 101: 13885-13890, 2004.
4. Morita S, Oka Y, Tsuboi A, Kawakami M, Maruno M, Izumoto S, Osaki T, Taguchi T, Ueda T, Myoui A, Nishida S, Shirakata T, Ohno S, Oji Y, Aozasa K, Hatazawa J, Udaka K, Yoshikawa H, Yoshimine T, Noguchi S, Kawase I, Nakatsuka S, Sugiyama H and Sakamoto J: A phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data. Jpn J Clin Oncol 36: 231-236, 2006.
5. Iiyama T, Udaka K, Takeda S, Takeuchi T, Adachi YC, Ohtsuki Y, Tsuboi A, Nakatsuka S, Elisseeva OA, Oji Y, Kawakami M, Nakajima H, Nishida S, Shirakata T, Oka Y, Shuin T and Sugiyama H: WT1 (Wilms' tumor 1) peptide immunotherapy for renal cell carcinoma. Microbiol Immunol 51: 519-530, 2007.
6. Tsuboi A, Oka Y, Nakajima H, Fukuda Y, Elisseeva OA, Yoshihara S, Hosen N, Ogata A, Kito K, Fujiki F, Nishida S, Shirakata T, Ohno S, Yasukawa M, Oji Y, Kawakami M, Morita S, Sakamoto J, Udaka K, Kawase I and Sugiyama H: Wilms' tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma. Int J Hematol 86: 414-417, 2007.
7. Izumoto S, Tsuboi A, Oka Y, Suzuki T, Hashiba T, Kagawa N, Hashimoto N, Maruno M, Elisseeva OA, Shirakata T, Kawakami M, Oji Y, Nishida S, Ohno S, Kawase I, Hatazawa J, Nakatsuka S, Aozasa K, Morita S, Sakamoto J, Sugiyama H and Yoshimine T: Phase II clinical trial of Wilms' tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. J Neurosurg 108: 963-971, 2008.
8. Ohno S, Kyo S, Myojo S, Dohi S, Ishizaki J, Miyamoto K, Morita S, Sakamoto J, Enomoto T, Kimura T, Oka Y, Tsuboi A, Sugiyama H and Inoue M: Wilms' tumor 1 (WT1) peptide immunotherapy for gynecological malignancy. Anticancer Res 29: 4779-4784, 2009.
9. Klebanoff CA, Gattinoni L and Restifo NP: CD8+ T-Cell memory in tumor immunology and immunotherapy. Immunol Rev 211: 214-224, 2006.
10. Fujiki F, Oka Y, Kawakatsu M, Tsuboi A, Tanaka-Harada Y, Hosen N, Nishida S, Shirakata T, Nakajima H, Tatsumi N, Hashimoto N, Taguchi T, Ueda S, Nonomura N, Takeda Y, Ito T, Myoui A, Izumoto S, Maruno M, Yoshimine T, Noguchi S, Okuyama A, Kawase I, Oji Y and Sugiyama H: A clear correlation between WT1-specific Th response and clinical response in WT1 CTL epitope vaccination. Anticancer Res 30: 2247-2254, 2010.
11. Ohno S, Takano F, Ohta Y, Kyo S, Myojo S, Dohi S, Sugiyama H, Ohta T and Inoue M: Frequency of myeloid dendritic cells can predict the efficacy of Wilms' tumor 1 peptide vaccination. Anticancer Res 31: 2447-2452, 2011.
12. Park LS, Friend D, Gillis S and Urdal DL: Characterization of the cell surface receptor for human granulocyte/macrophage colony-stimulating factor. J Exp Med 164: 251-262, 1986.
13. Grabstein KH, Urdal DL, Tushinski RJ, Mochizuki DY, Price VL, Cantrell MA, Gillis S and Conlon PJ: Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor. Science 232: 506-508, 1986.
14. Weiner GJ, Liu HM, Wooldridge JE, Dahle CE and Krieg AM: Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci USA 94: 10833-10837, 1997.
15. Bauer S and Wagner H: Bacterial CpG-DNA licenses TLR9. Curr Top Microbiol Immunol 270: 145-154, 2002.
16. Tsuboi A, Oka Y, Udaka K, Murakami M, Masuda T, Nakano A, Nakajima H, Yasukawa M, Hiraki A, Oji Y, Kawakami M, Hosen N, Fujioka T, Wu F, Taniguchi Y, Nishida S, Asada M, Ogawa H, Kawase I and Sugiyama H: Enhanced induction of human WT1-specific cytotoxic T-lymphocytes with a 9-mer WT1 peptide modified at HLA-A&z.ast;2402-binding residues. Cancer Immunol Immunother 51: 614-620, 2002.
17. Li Z, Oka Y, Tsuboi A, Fujiki F, Harada Y, Nakajima H, Masuda T, Fukuda Y, Kawakatsu M, Morimoto S, Katagiri T, Tatsumi N, Hosen N, Shirakata T, Nishida S, Kawakami Y, Udaka K, Kawase I, Oji Y and Sugiyama H: Identification of a WT1 protein-derived peptide, WT1, as a HLA-A 0206-restricted, WT1-specific CTL epitope. Microbiol Immunol 52: 551-558, 2008.
18. Nakatsuka S, Oji Y, Horiuchi T, Kanda T, Kitagawa M, Takeuchi T, Kawano K, Kuwae Y, Yamauchi A, Okumura M, Kitamura Y, Oka Y, Kawase I, Sugiyama H and Aozasa K: Immunohistochemical detection of WT1 protein in a variety of cancer cells. Mod Pathol 19: 804-814, 2006.
19. the National Cancer Institute Common Terminology Criteria for Adverse Events ver. 3.0: http://ctep.cancer.gov/protocolDevelopment/electronic- applications/docs/ctcaev3.pdf
20. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
21. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM and Matrisian LM: The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 15: 5323-5337, 2009.
22. Borrello I and Pardoll D: GM-CSF-based cellular vaccines: a review of the clinical experience. Cytokine Growth Factor Rev 13: 185-193, 2002.
23. Villinger F: Cytokines as clinical adjuvants: How far are we? Expert Rev Vaccines 2: 317-326, 2003.
24. Chang DZ, Lomazow W, Joy Somberg C, Stan R and Perales MA: Granulocyte-macrophage colony stimulating factor: an adjuvant for cancer vaccines. Hematology 9: 207-215, 2004.
25. Rezvani K, Yong AS, Mielke S, Savani BN, Musse L, Superata J, Jafarpour B, Boss C and Barrett AJ: Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 111: 236-242, 2008.
26. Keilholz U, Letsch A, Busse A, Asemissen AM, Bauer S, Blau IW, Hofmann WK, Uharek L, Thiel E and Scheibenbogen C: A clinical and immunologic phase 2 trial of Wilms' tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 113: 6541-6548, 2009.
27. Rezvani K, Yong AS, Mielke S, Jafarpour B, Savani BN, Le RQ, Eniafe R, Musse L, Boss C, Kurlander R and Barrett AJ: Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T-cells in myeloid malignancies. Haematologica 96: 432-440, 2011.
28. Krug LM, Dao T, Brown AB, Maslak P, Travis W, Bekele S, Korontsvit T, Zakhaleva V, Wolchok J, Yuan J, Li H, Tyson L and Scheinberg DA: WT1 peptide vaccinations induce CD4 and CD8 T-cell immune responses in patients with mesothelioma and non-small cell lung cancer. Cancer Immunol Immunother 59: 1467-1479, 2010.
29. Speiser DE, Liénard D, Rufer N, Rubio-Godoy V, Rimoldi D, Lejeune F, Krieg AM, Cerottini JC and Romero P: Rapid and strong human CD8+ T-cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J Clin Invest 115: 739-746, 2005.
30. Valmori D, Souleimanian NE, Tosello V, Bhardwaj N, Adams S, O'Neill D, Pavlick A, Escalon JB, Cruz CM, Angiulli A, Angiulli F, Mears G, Vogel SM, Pan L, Jungbluth AA, Hoffmann EW, Venhaus R, Ritter G, Old LJ and Ayyoub M: Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T-cells through cross-priming. Proc Natl Acad Sci USA 104: 8947-8952, 2007.
31. Molenkamp BG, Sluijter BJ, van Leeuwen PA, Santegoets SJ, Meijer S, Wijnands PG, Haanen JB, van den Eertwegh AJ, Scheper RJ and de Gruijl TD: Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patients. Clin Cancer Res 14: 4532-4542, 2008.
32. Molenkamp BG, van Leeuwen PA, Meijer S, Sluijter BJ, Wijnands PG, Baars A, van den Eertwegh AJ, Scheper RJ and de Gruijl TD: Intradermal CpG-B activates both plasmacytoid and myeloid dendritic cells in the sentinel lymph node of melanoma patients. Clin Cancer Res 13: 2961-2969, 2007.
33. Karbach J, Gnjatic S, Bender A, Neumann A, Weidmann E, Yuan J, Ferrara CA, Hoffmann E, Old LJ, Altorki NK and Jäger E: Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival. Int J Cancer 126: 909-918, 2010.
34. Iwahashi M, Katsuda M, Nakamori M, Nakamura M, Naka T, Ojima T, Iida T and Yamaue H: Vaccination with peptides derived from cancer-testis antigens in combination with CpG-7909 elicits strong specific CD8+ T-cell response in patients with metastatic esophageal squamous cell carcinoma. Cancer Sci 101: 2510-2517, 2010.
35. Krieg AM: CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20: 709-760, 2002.
36. Ballas ZK, Krieg AM, Warren T, Rasmussen W, Davis HL, Waldschmidt M and Weiner GJ: Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J Immunol 167: 4878-4886, 2001.
37. Weber JS, Zarour H, Redman B, Trefzer U, O'Day S, van den Eertwegh AJ, Marshall E and Wagner S: Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma. Cancer 115: 3944-3954, 2009.
38. Hong S, Qian J, Li H, Yang J, Lu Y, Zheng Y and Yi Q: CpG or IFN-α are more potent adjuvants than GM-CSF to promote antitumor immunity following idiotype vaccine in multiple myeloma. Cancer Immunol Immunother 61: 561-571, 2012.
39. WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland: World Health Organization Offset Publication No. 48, 1979.
40. Berd D, Sato T, Cohn H, Maguire HC Jr and Mastrangelo MJ: Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: regression of pulmonary metastases. Int J Cancer 94: 531-539, 2001.
41. Kruit WH, van Ojik HH, Brichard VG, Escudier B, Dorval T, Dréno B, Patel P, van Baren N, Avril MF, Piperno S, Khammari A, Stas M, Ritter G, Lethé B, Godelaine D, Brasseur F, Zhang Y, van der Bruggen P, Boon T, Eggermont AM and Marchand M: Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Int J Cancer 117: 596-604, 2005.
42. van Baren N, Bonnet MC, Dréno B, Khammari A, Dorval T, Piperno-Neumann S, Liénard D, Speiser D, Marchand M, Brichard VG, Escudier B, Négrier S, Dietrich PY, Maraninchi D, Osanto S, Meyer RG, Ritter G, Moingeon P, Tartaglia J, van der Bruggen P, Coulie PG and Boon T: Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T-cells. J Clin Oncol 23: 9008-9021, 2005.
43. Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A, Macrae S, Nelson M, Canning C, Lowy I, Korman A, Lautz D, Russell S, Jaklitsch MT, Ramaiya N, Chen TC, Neuberg D, Allison JP, Mihm MC and Dranoff G: Immunologic and clinical effects of antibody blockade of cytotoxic T-lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA 105: 3005-3010, 2008.
44. Dohi S, Ohno S, Ohno Y, Takakura M, Kyo S, Soma G, Sugiyama H and Inoue M: WT1 peptide vaccine stabilized intractable ovarian cancer patient for one year: a case report. Anticancer Res 31: 2441-2445, 2011.
45. Hoos A, Parmiani G, Hege K, Sznol M, Loibner H, Eggermont A, Urba W, Blumenstein B, Sacks N, Keilholz U and Nichol G; Cancer Vaccine Clinical Trial Working Group: A clinical development paradigm for cancer vaccines and related biologics. J Immunother 30: 1-15, 2007.